.
MergerLinks Header Logo

New Deal

New Deal

Cover Image Oleg Nodelman
Oleg NodelmanECOR1 CAPITAL

Oleg Nodelman

Founder and CEO at ECOR1 CAPITAL

Investor

Deal Bio

Total Deals16
Valued Deals15
Total Value£4,005M
Avg. Deal Size£267M

Expertise (16)

Key Relationships

United States
Biotechnology
PrivatePrivate EquityAcquisitionMinorityVenture Capital
Nuvation Bio

target

Nuvation Bio

Baupost Group

bidder

Baupost Group

£214m

13 dealmakers

United States
Biotechnology
PrivateVenture CapitalPrivate EquityMinorityAcquisition
Elevatebio

target

Elevatebio

The Invus Group

bidder

The Invus Group

£137m

24 dealmakers

United States
Biotechnology
PrivateAcquisitionPrivate EquityVenture CapitalMinority
Shattuck Labs

target

Shattuck Labs

Hatteras Venture Partners

bidder

Hatteras Venture Partners

£94m

15 dealmakers

United States
Biotechnology
Private EquityMinorityAcquisitionPublicReverse TakeoverDomesticDe-SPAC
Cerevel Therapeutics

target

Cerevel Therapeutics

Ecor1 Capital

bidder

Ecor1 Capital

£1,002m

66 dealmakers

Canada
Biotechnology
AcquisitionMinorityPrivate EquityPrivateVenture Capital
Chinook Therapeutics

target

Chinook Therapeutics

Ecor1 Capital

bidder

Ecor1 Capital

£80m

15 dealmakers

United States
Pharmaceuticals
MinorityAcquisitionVenture CapitalPrivatePrivate Equity
Kronos Bio

target

Kronos Bio

Perceptive Advisors

bidder

Perceptive Advisors

£118m

18 dealmakers

Netherlands
Biotechnology
MinorityCross BorderPrivate EquityAcquisitionPrivateVenture Capital
Neogene Therapeutics

target

Neogene Therapeutics

Jeito Capital

bidder

Jeito Capital

£85m

26 dealmakers

United States
Biotechnology
PrivateMajorityAcquisitionReverse TakeoverMergerDomesticPrivate EquityDe-SPAC
Nuvation Bio

target

Nuvation Bio

Panacea Acquisition Corp

bidder

Panacea Acquisition Corp

£650m

34 dealmakers

United States
Biotechnology
Private EquityPrivateMinorityAcquisitionVenture CapitalDomestic
Neurogene

target

Neurogene

Casdin Capital

bidder

Casdin Capital

£85m

14 dealmakers

United Kingdom
Pharmaceuticals
MinorityPrivate EquityAcquisitionPrivateCross BorderVenture Capital
Centessa Pharmaceuticals

target

Centessa Pharmaceuticals

Janus Henderson Investors

bidder

Janus Henderson Investors

£179m

27 dealmakers

United States
Biotechnology
DomesticVenture CapitalPrivate EquityPrivateMinorityAcquisition
Artiva Biotherapeutics

target

Artiva Biotherapeutics

Acuta Capital

bidder

Acuta Capital

value n/a

16 dealmakers

United States
Biotechnology
AcquisitionMinorityPrivate EquityPrivateCross BorderVenture Capital
Elevatebio

target

Elevatebio

Matrix Capital Management

bidder

Matrix Capital Management

£376m

25 dealmakers

United States
Biotechnology
Private EquityDe-SPACReverse TakeoverPrivateDomesticMergerAcquisitionMajority
Tango Therapeutics

target

Tango Therapeutics

Cormorant Asset Management

bidder

Cormorant Asset Management

£257m

32 dealmakers

United States
Biotechnology
AcquisitionPrivateDomesticMinorityPrivate EquityVenture Capital
Nikang Therapeutics

target

Nikang Therapeutics

Surveyor Capital

bidder

Surveyor Capital

£141m

29 dealmakers

United States
Biotechnology
MajorityMergerDe-SPACPrivate EquityDomesticAcquisitionPrivateReverse Takeover
Pardes Biosciences

target

Pardes Biosciences

Ecor1 Capital

bidder

Ecor1 Capital

£199m

37 dealmakers

United States
Biotechnology
PrivateCross BorderAcquisitionMinorityPrivate EquityVenture Capital
Eikon Therapeutics

target

Eikon Therapeutics

Harel Group

bidder

Harel Group

£382m

21 dealmakers

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US